BOLERO-2

NCT00863655 📎

Regimen

Experimental
Everolimus 10 mg daily plus exemestane 25 mg daily.
Control
Placebo plus exemestane 25 mg daily.

Population

Postmenopausal women with HR+/HER2- advanced breast cancer who had progressed on a nonsteroidal aromatase inhibitor.

Key finding

BOLERO-2 was the first phase 3 trial to show that adding a targeted agent (the mTOR inhibitor everolimus) to endocrine therapy improves outcomes in AI-resistant HR+ metastatic disease. Anchored everolimus plus exemestane in NCCN BINV-P as an option after AI progression, especially when CDK4/6 + SERD/fulvestrant options are exhausted.

Source: PMID 22149876

Timeline

  • Publication: 2012 Feb 9

Guideline citations

  • NCCN BREAST